Document Detail

Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
MedLine Citation:
PMID:  21052764     Owner:  NLM     Status:  In-Data-Review    
It is often difficult to manage refractory gastrointestinal tract complications of Behçet's disease (entero-BD) by conventional therapy. In this study, we assessed the short- and long-term efficacy and safety of the combination therapy of infliximab, an anti-tumor-necrosis-factor (TNF)-α antibody, and methotrexate in ten patients with refractory entero-BD refractory to conventional therapies. The short- (weeks) and long-term (by 2 years) effects of infliximab at 3-5 mg/kg body weight every 8 weeks on the clinical course and intestinal manifestations were assessed by abdominal computed tomography (CT) and colonoscopy. The primary endpoint was the rate of disappearance of ileocecal ulceration at 12 months of therapy. All patients showed improvement of gastrointestinal symptoms and disease-associated complications within 4 weeks. Furthermore, the rate of disappearance of ileocecal ulcerations was 50% (5/10 patients) at 6 months and 90% (9/10 patients) at 12 months, and, therefore 90% of patients were satisfied with the primary endpoint. Furthermore, corticosteroid dose was significantly reduced from 22.0 to 1.8 mg/day at 24 months. No severe adverse effects were observed during the 24 months of follow-up. We provide evidence for the rapid and excellent efficacy of infliximab in patients with refractory entero-BD and that the combination of infliximab and methotrexate brings about long-term alleviation of entero-BD and excellent tolerability.
Shigeru Iwata; Kazuyoshi Saito; Kunihiro Yamaoka; Shizuyo Tsujimura; Masao Nawata; Kentaro Hanami; Yoshiya Tanaka
Related Documents :
23134924 - Effect of maternal oral hydration therapy in oligohydramnios.
23949654 - Management of the treatment delay in symptomatic carotid artery stenosis.
25105874 - Weight loss by telemonitoring of nutrition and physical activity in patients with metab...
12905464 - Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose ...
21148264 - Observations during an elective interruption of natalizumab treatment: a post-marketing...
19615804 - Effect of a carbonaceous oral adsorbent on the progression of ckd: a multicenter, rando...
Publication Detail:
Type:  Journal Article     Date:  2010-11-05
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  21     ISSN:  1439-7609     ISO Abbreviation:  Mod Rheumatol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-04-07     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  184-91     Citation Subset:  IM    
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahata-nishi, Kitakyushu, 807-8555, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung dis...
Next Document:  Tracking the heterogeneous distribution of amyloid spherulites and their population balance with fre...